Logo for ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Investor Relations Material

Latest events

Logo for ACADIA Pharmaceuticals Inc

Q4 2023

ACADIA Pharmaceuticals
Logo for ACADIA Pharmaceuticals

Q4 2023

27 Feb, 2024
Logo for ACADIA Pharmaceuticals

Q3 2023

2 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from ACADIA Pharmaceuticals Inc

Access all reports
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on improving the lives of patients with serious central nervous system disorders. The Company has a clinical program to assess the safety, efficacy and pharmacokinetic profile of pimavanserin (RE-021), an investigational drug that acts as a selective serotonin 5-hydroxytryptamine 2A receptor inverse agonist (SSRI) to study the central serotonergic system pharmacology and physiology in healthy volunteers and patients with Parkinson's disease psychosis (PDP).